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Abstract Microvascular endothelial cells display a large
degree of heterogeneity in function depending on their
location in the vascular tree. The existence of organ-
specific, microvascular-bed-specific, and even intravascular
variations in endothelial cell gene expression emphasizes
their high cell-to-cell variability, which is furthermore
extremely adaptable to altering conditions. The ability of
microvascular endothelial cells to respond dynamically to
pathology-related microenvironmental changes is particu-
larly apparent in tumor-growth-associated angiogenesis. An
understanding of how they behave, how their behavior
varies between and within tumors, and how their behavior
is related to responsiveness to drugs is critical for the
development of effective anti-angiogenic treatment strate-
gies. In this review, we introduce some general issues
concerning organ-imprinted microvascular heterogeneity
and highlight the importance of studying microvascular
endothelial cell behavior in an in vivo context. This is
followed by an overview of state-of-the-art knowledge
regarding the nature of the variation in microenvironmental
conditions in pre-clinical and clinical tumors and their
consequences for tumor endothelial behavior. We provide
recent insights into the in vivo molecular activation status
of the endothelium and, finally, outline our current
understanding of the way that anti-angiogenic drugs affect
tumor endothelial cells in relation to their anti-tumor
effects.
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Introduction
Endothelial cells line the interior surface of all blood
vessels in the body, from the largest conduit vessels to the
smaller resistance vessels and the capillaries in the organs.
The microvasculature in the major organs exerts functions
specific for each organ. For example, the microvasculature
in the brain is an integral part of the tight blood-brain-
barrier, whereas in the liver, the sinusoidal endothelial cells
engage in the efficient clearing of numerous molecular
entities from the body. In the kidneys, the glomerular
endothelium acts as a semi-permeable membrane for the
filtration of blood-borne components, and the descending
and ascending vasa recta or peritubular capillaries engage
in the re-absorption and excretion of components into,
respectively from the blood circulation (Aird 2007). Fur-
thermore, the smallest blood vessels of the body especially
engage in disease-related processes such as the new
formation of blood vessels that accompanies wound
healing, tissue repair, and solid tumor growth (see below)
and leukocyte recruitment during an inflammatory insult
(Pober and Sessa 2007).
The microvasculature consists of endothelial cells and
scarce support cells; hence, microvascular involvement in
health and disease is strongly controlled by the behavior of
the endothelial cells. At present, we are rather ignorant with
regard to the molecular definition of the heterogeneity that
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underlies organ-specific microvascular endothelial function
and engagement in disease. Beyond any doubt, this
functional heterogeneity is guided by variations in the
biochemical and biomechanical properties of the local
environment. For a pharmacologist, an understanding of
the molecular control of microvascular endothelial cell
function in normal and pathological conditions is of
essential importance to be able to interfere successfully
with a disease without affecting normal vasculature.
In the current review, we will briefly introduce some
general considerations regarding microvascular endothelial
heterogeneity in adult organs. From there on, we will focus
on tumor-growth-related angiogenesis and review the state-
of-the-art knowledge hitherto generated with respect to
microenvironmental heterogeneity between and within
tumors. We provide a concise, though not absolute,
inventory of what is known about the responses of tumor
endothelial cells to local tumor and host conditions and
about our current understanding of the way that anti-
angiogenic drugs affect endothelial cells. The focus will be
on anti-vascular endothelial growth factor (VEGF) thera-
peutics as these have been most extensively studied in
preclinical and clinical settings. In the general conclusion,
we will briefly touch on a few issues that have not been
addressed here in detail, because of space limitations, but
that should be taken into account in our quest to
therapeutically address cells that, despite being discovered
almost 400 years ago, remain elusive, even today.
Heterogeneity of endothelial cells
The mesoderm is the exclusive source of endothelial cell
precursors during embryogenesis. The close co-localization
of endothelial and hematopoietic precursor cells within the
embryo and the finding that these cells both bear universal
molecular markers have given rise to the concept that both
lineages arise from the hemangioblast as a common
precursor (Patterson 2007). In the adult body, endothelial
cells in quiescent vasculature are proliferative inactive, with
a life-span of >100 days in the main organs, as reported
more than two decades ago by Denekamp and colleagues
(Hobson and Denekamp 1984). Pro-inflammatory and pro-
angiogenic activation as a consequence of physiological
stimuli or trauma activates the endothelium. Upon resolu-
tion of the inciting stimuli, the cells tend to regain a
quiescent phenotype, among others via the expression of
protective genes A20 and A1 (Ferran 2006), phosphatases,
and other molecular inhibitors of pro-inflammatory signal
transduction (Winsauer and de Martin 2007). Under certain
conditions, including both small disturbances and larger
insults, the induction of endothelial cell death takes place,
as has been observed, for example, in antineutrophil
cytoplasmic antibody-associated vasculitis (de Groot et al.
2007), in renal ischemia (Horbelt et al. 2007), and in solid
tumor growth (de Jong et al. 2006). The potential role of
circulating CD34+ hematopoietic and endothelial precursor
cells in microvascular repair (de Groot et al. 2007) suggests
the intriguing possibility that microvascular endothelial
replacement can take place in the absence of endothelial
proliferation. Hence, the life span of the endothelial
compartment may be significantly shorter than previously
estimated, with concurrent variability in the general status
of the endothelial cells.
For many pre-clinical and clinical applications, the
availability of molecular antigens to identify the endothelial
cells in a tissue is of great importance. A large variety of
endothelial marker genes have been proposed for this
purpose (Table 1), a few of them being truly endothelial-
specific, whereas the majority can be categorized as
endothelial-restricted. In addition to the existence of species
differences in the expression patterns of these markers,
microvascular subset-restricted expression, organ-depen-
dent microvascular bed-restricted expression, and patchy
marker gene expression indicative of cell-to-cell variability
within a microvascular bed have been reported (Muller et
al. 2002; Samulowitz et al. 2002; Pusztaszeri et al. 2006).
The highly heterogenic presentation of endothelial cells
throughout the body invites one to pose the (rhetorical)
question of what makes an endothelial cell an endothelial
cell? It should not only look like an endothelial cell, but
should also behave like an endothelial cell and communi-
cate like an endothelial cell. All endothelial cells have the
common characteristic that they line the vessels of the
blood circulatory system that range from centimeters in
diameter in the aorta to a few micrometers in diameter
in the smallest capillaries in the organs. They are all thus in
direct contact with the blood and all exert pronounced anti-
coagulant activity via, among others, the expression of
tissue factor pathway inhibitors, heparan sulphate proteo-
glycans that interfere with thrombin-controlled coagulation,
and thrombomodulin. By this means, whole body homeo-
stasis and hemostasis is secured, until (patho)physiological
stimuli disrupt the status quo.
We recently investigated the expression patterns of a
number of well-accepted endothelial marker genes, viz.,
CD31, vascular endothelial (VE)-cadherin, plasmalemmal
vesicle (PV)-1, Endomucin, and von Willebrand factor
(vWF), and the cell adhesion molecules E-selectin, vascular
cell adhesion molecule (VCAM)-1, and intercellular adhe-
sion molecule (ICAM)-1 in the five main organs of
10-week-old C57Bl/6 mice. Using immunohistochemistry,
we showed that, even with this small number of molecular
entities, a remarkable heterogenic endothelial signature
became visible (Fig. 1; J. Kułdo and G. Molema,
unpublished). This supports the idea that, although all
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endothelial cells have a number of characteristics in
common, they are under the control, in each microvascular
bed, of a combination of genes unique for that specific
vascular bed (Aird 2006). From this, one has to conclude
that the endothelial cell does not exist, and that each cell
needs to be appreciated with regard to its own identity and
functionality in relation to its location in the vascular tree.
Flexibility of endothelial cells to adapt to local
conditions
The behavior of endothelial cells in the (micro)vasculature
is intricately controlled by the microenvironment. Biolog-
ical factors including extracellular matrix (ECM) compo-
nents and locally produced growth factors, interactions
Table 1 Endothelial cell (EC)-restricted genes used to identify microvasculature in tissues. Expression patters of some of the markers in human
tissues may be found in the Human Protein Atlas (at http://www.proteinatlas.org/index.php)




Angiotensin; lung capillary EC and EC of larger arteries and arterioles Stevens 2007
αvβ3 RGD-containing ligands; extra-alveolar and alveaolar capillary EC, mild
expression in hepatic portal vein
Singh et al. 2000
CD31 CD31 on EC, leukocytes; glycosaminoglycans; pan-endothelial marker Pusztaszeri et al. 2006;
Feng et al. 2004
CD34 L-selectin Pusztaszeri et al. 2006
CD141 (thrombomodulin) Thrombin; pan-endothelial marker Boffa et al. 1987
CD144 (VE-cadherin) CD144 homotypic interaction; pan-endothelial marker Prandini et al. 2005
Endomucin Unknown ligand Samulowitz et al. 2002
CD105 (endoglin) Transforming growth factor-β1 (TGF-β1) and –β3 in association with TGF-
β receptor type II
Fonsatti et al. 2001
Endothelin-1 (ET-1) ET receptors ETAR and ETBR Nelson et al. 2003
Ephrin B2 EphB4; preferred, not selective expression on arterial EC Gale et al. 2001
EphB4 Ephrin B2; preferred expression on venule EC Taylor et al. 2007
Fli-1 Ligand unknown Pusztaszeri et al. 2006
Plasmalemmal vesicle-1 (PV-1) Ligand unknown; expressed in stomatal and fenestral diaphragms of a subset
of EC in the smaller capillaries of some organs
Stan 2007
Tie-2 Angiopoietins Wong et al. 1997
Vascular adhesion protein (VAP)-1 Unknown ligand; expressed on EC in a subset of blood vessels Salmi et al. 1993
Vascular endothelial growth factor
receptor 2 (VEGFR-2)
VEGF; expressed on the majority of EC Jakeman et al. 1992
von Willebrand Factor (vWF)/
factor-VIII-related antigen
Factor VIII Pusztaszeri et al. 2006
Disease-induced endothelial expression
αvβ3 integrin RGD sequence containing (poly)peptides Schnell et al. 2008
CD54 (ICAM-1) LFA-1 integrin van Meurs et al. 2008
CD62P (P-selectin) Carbohydrate determinants on selectin ligands, e.g., PSGL-1 Carvalho-Tavares et al.
2000
CD62E (E-selectin) Sialyl-Lewis-X antigen and other carbohydrates Asgeirsdottir et al. 2007
CD105 (endoglin) TGF-β1 and –β3 in association with TGF-β receptor type II; overexpressed
on angiogenic EC
Fonsatti et al. 2001
CD106 (VCAM-1) VLA-4 integrin Inoue et al. 2006
Endothelin receptorB (ETBR) ET-1 Buckanovich et al. 2008
PV-1 Ligand unknown; upregulated in brain tumors Carson-Walter et al.
2005
R-AGE (receptor for advanced
glycation end products)
AGEs Soulis et al. 1997
Tie-2 Angiopoietins Fathers et al. 2005
VAP-1 Leukocyte extravasation support Jalkanen and Salmi
2008
VEGFR-2 VEGF Brown et al. 1997
a References in this section refer to published work in which in vivo microvascular or organ-specific heterogeneity in the expression of the gene
was specifically addressed. For the majority of markers summarized, publications regarding their original identification can be found in Garlanda
and Dejana (1997)
























Fig. 1 Microvascular heterogeneity in perspective. a Representation
of the cellular make-up and dimensions of the microvasculature in
relation to the size of blood-borne cells. Whereas the last feeding
arterioles are covered by a few layers of smooth muscle cells,
capillaries and the first segment of the postcapillary venules are only
covered by sparse pericytes. During an inflammatory insult, leuko-
cytes mainly transmigrate from the blood into the tissue in the
capillary and the postcapillary segments of the microvasculature.
Angiogenesis is thought to take place mainly in the first segments of
the postcapillary venules. For clarity, the collagen layer surrounding
the arterioles (visible in b) was left out. b Immunohistochemical
detection of Endomucin in mouse brain showing a clear demarcation
between Endomucin-negative arterioles (a) and Endomucin-positive
capillaries (c) and postcapillary venules (pv). Note that, in the
postcapillary venules, Endomucin expression is not equally distributed
among endothelial cells, thereby representing an additional level of
endothelial heterogeneity. c Summary of expression of endothelial
marker genes and adhesion molecules in different microvascular
segments in 10-week-old C57Bl/6 mouse organs as assessed by
immunohistochemistry (endocard endocardium). The kidneys have
two capillary segments with specific functions, i.e., the glomerular
microvasculature and the peritubular or vasa recta microvasculature.
Although some peritubular endothelial cells expressed VCAM-1 under
normal conditions, glomerular expression is not detectable. ICAM-1 is
strongly expressed by all peritubular endothelial cells and to a lesser
extent in the glomeruli (unpublished)
208 Cell Tissue Res (2009) 335:205–222
with neighboring cells, leukocytes, erythrocytes, platelets,
and other constituents of the blood, and mechanical forces
all influence general cell performance. The readiness of
these cells to adapt to local changes was elegantly
demonstrated in a mouse model for inter-positioning a
venous segment into the arterial circulation, as occurs
during coronary artery bypass surgery in the clinic. Upon
connecting the external jugular vein to the common
carotid artery, the endothelial cells covering the venular
wall phenotypically shifted toward arterial endothelial
behavior. This was accompanied by an increase in smooth
muscle cell layers and microvessel ingrowth in the outer
vascular wall, and the loss of vascular permeability func-
tion (Kwei et al. 2004).
Almost similarly effortless is their adaptation to in vitro
culture conditions. Many primary endothelial cell cultures
and cell lines have been phenotyped for gene expression
under normal culture conditions (Muller et al. 2002; Mutin
et al. 1997; Chi et al. 2003). However, their in vitro
behavior is not a perfect reflection of the in vivo situation.
For example, glomerular endothelial cells gain expression
of vWF upon culturing (Satchell et al. 2006), whereas vWF
is almost absent in this part of the microvascular tree in
vivo (Pusztaszeri et al. 2006). Recently, Liu et al. (2008)
demonstrated that in situ human umbilical artery and
human umbilical vein endothelial cells (HUVEC) exerted
dramatic differences in tumor necrosis factor (TNF)α-
mediated E-selectin expression capacity. In situ in the
umbilical cord, transcription factor and p300 coactivator
recruitment to the enhancer sequence in the E-selectin
promoter was reduced in the artery endothelial cells
compared with vein endothelial cells. Within 72 h of in
vitro culture, however, the artery and vein endothelial cells
became almost indistinguishable in this molecular control
of their response to TNFα (Liu et al. 2008). Vice versa, Bcl-
2-transduced HUVEC can become an integrated part of
arterioles, capillaries, and venules in vivo with accompa-
nying vascular subset-specific responses to TNFα. This
implies that endothelial cell behavior is not based on cell
fate decisions but a context-driven phenomenon (Enis et al.
2005).
Tumor angiogenesis is an exquisite circumstance in
which microvascular endothelial cells can demonstrate the
full potential of their adaptability to continuously changing
conditions. In the remainder of this review, we will describe
the nature of these conditions and how they depend on a
large variety of factors, both in preclinical animal models
and, where possible, in patient material. We will discuss the
consequences of changing tumor conditions for endothelial
behavior, and the pharmacological challenges associated
with both tumor endothelial heterogeneity and tumor
endothelial adaptability.
Tumor endothelial heterogeneity and its consequences
for anti-angiogenic therapy
Angiogenesis is one of the main processes by means of
which a tumor creates its own oxygen and nutrient supply
and a route for systemic metastasis (Folkman 1971). It is
tightly regulated and starts with the activation of (post-
capillary) endothelial cells in pre-existing blood vessels,
followed by the induction of vasodilation and an increase in
endothelial cell permeability. ECM-degrading proteinases
next degrade the endothelial basement membrane to allow
the proliferating endothelial cells to penetrate into the tumor
mass. The proliferation and migration of the endothelial
cells result in the formation of endothelial tube structures.
The newly formed vasculature matures upon interaction
with ECM and mesenchymal cells, with mural cells (or
pericytes) being recruited to form a surrounding support
layer. Once new vessels have assembled, the endothelial
cells become quiescent, and the vessels turn resistant to, for
example, VEGF withdrawal (Conway et al. 2001; Auguste
et al. 2005; Benjamin et al. 1999). The different angiogenic
stages of the vasculature, from newly formed pre-mature
sprout to fully stabilized mature new blood vessel, are
precisely regulated by microenvironmental balances of pro-
and anti-angiogenic molecules (Griffioen and Molema
2000).
The mechanistic repertoire that tumor cells use to
regulate new vessel formation is diverse and may alter for
a given tumor type or host environment. In addition to
angiogenesis, other mechanisms have been recognized to
contribute to tumor vascularization. These include recruit-
ment of angioblasts, co-option of pre-existing blood
vessels, and vasculogenic mimicry, the presence of blood-
filled channels being lined by tumor cells rather than
endothelial cells (Auguste et al. 2005; Hillen and Griffioen
2007). These different mechanisms may exist at the same
time in the same tumor or may be selectively active in a
specific tumor type or host environment (Auguste et al.
2005). For instance, uveal melanoma establishes its vascula-
ture partially through vascular mimicry in the eye (Maniotis
et al. 1999) but through both vasculogenic mimicry and
sprouting angiogenesis when implanted subcutaneously (s.c.;
Hendrix et al. 2003). Although the occurrence of vasculo-
genic mimicry in these uveal melanomas has been questioned
by McDonald and Foss (McDonald and Foss 2000), who
have shown clear endothelial lining of the blood vessels, this
example nevertheless clearly illustrates the variety in mech-
anisms employed by tumors to acquire their vasculature.
Tumor blood vessels are often abnormal, being character-
ized by increased permeability, tortuosity, excessive random
branching, and intratumoral variations in vascular lumen size.
Many tumor vessels have abluminal endothelial sprouts that
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penetrate deep into the perivascular tumor tissue and show
aberrant patterns of pericyte investment, with pericytes loosely
attached to the vessel wall and extending away from the vessel
surface. Furthermore, they lack the defining structural features
of arterioles, capillaries, or venules (Pasqualini et al. 2002;
McDonald and Foss 2000; Abramsson et al. 2002; Morikawa
et al. 2002). Heterogeneous vascular morphology has been
described in various tumor types, in tumors from the same
origin growing in different host environment, and in different
stages of tumor progression, and even zonal vascular
heterogeneity within one tumor stage has been observed. In
addition to differences in vascular morphology, the endothe-
lial fenestration pattern, pericyte association, and gene
expression profile of the respective vasculatures are often
variable, as will be discussed below.
A landmark study of the therapeutic efficacy of anti-
angiogenic drugs with various molecular targets and
administered at different stages of tumor outgrowth
published by Bergers et al. in 1999 demonstrated that the
anti-tumor efficacy of the angiogenesis inhibitors was
tumor-stage-specific (Fig. 2). Whereas some inhibitors
were more effective in reducing tumor growth when
administered at the early stage of tumor progression, others
showed better anti-tumor activity in late-stage disease. Until
now, neither the underlying molecular mechanisms of (lack
of) responses of tumor and tumor endothelial cells to the
different anti-angiogenic therapies nor their relationships to
anti-tumor activity have been elucidated. Moreover, in
many animal and human tumors, these issues have been
poorly addressed. As they are critical for the successful
development of anti-angiogenic drugs, we will provide an
overview on what is currently known about the variation in
microenvironmental conditions that exist in tumors and its
consequences for tumor endothelial behavior and anti-
angiogenic drug effects.
Variations in tumor microenvironment that affect
the angiogenic status of a tumor
As briefly referred to above, microvascular heterogeneity
exists at different levels. This heterogeneity is brought
about by variations in tumor cell dependency on the blood
supply, the host environment in which the tumor grows, the
tumor growth stage, and ill-defined local spatiotemporal
differences in angiogenic gene expression by tumor,
stromal, and infiltrating immune cells (Fig. 3).
Not all tumor cells depend in a similar way on the blood
supply
As has been known for many decades, tumor cells within a
tumor are highly heterogeneous with regard to genotypic
and phenotypic characteristics such as proliferation rate,
survival mechanisms, and capabilities to form metastases
(Fidler and Hart 1982; Heppner 1984). Furthermore, the
degree to which individual tumor cells rely on the blood
supply varies, resulting in the presence of subpopulations of
tumor cells with different angiogenic activities within one
tumor (Fig. 3a). Isolation and subsequent subcutaneous or
intradermal inoculation of these subpopulations into mice
gave rise to tumors with different microvascular densities
(MVD), apoptotic rates, and growth characteristics (Achilles
et al. 2001; Yu et al. 2001). Tumors resulting from injection
of cell populations originally located distal from the tumor
vasculature had enhanced tumor growth rates and a lower
number of vWF-positive blood vessels, whereas cell pop-
ulations proximal to the vasculature gave rise to less
aggressive tumors with higher numbers of vWF-positive
blood vessels (Yu et al. 2001). Similarly, high-grade human
renal cell carcinomas were associated with a different
angiogenic pattern than low-grade tumors, with greater
endothelial cell proliferation, larger and more immature
vessels, but a lower MVD (Baldewijns et al. 2007). Thus,
variation in the dependency of tumor cell subpopulations on
their blood supply partly causes the variability in structure
and density of the vasculature that is acquired by the
different tumors.
Tumor vascular behavior depends on the host environment
Both in mice and man, neovasculature in identical tumor
types can be drastically different with regard to vascular
architecture, MVD, permeability, and gene expression when
the tumors are grown in different locations in the body. The
vasculature of tumors tends to acquire characteristics
similar to those of the host environment. For example, the
microvasculature of murine mammary carcinoma, rhabdo-
myosarcoma, and human glioblastoma implanted s.c. in
nude mice became extensively fenestrated, with a large
population of caveolae and a relatively high permeability,
similar to the host endothelium in the subcutaneous space
(Roberts et al. 1998). In contrast, the same tumors
implanted in the brain acquired a microvasculature that is
considerably less fenestrated, resembling more closely the
brain microvascular phenotype. Similar host environment-
induced variations in vascular morphology and/or perme-
ability have been described in mouse models for mammary
fat pad carcinoma (Monsky et al. 2002) and colon
carcinoma (Fukumura et al. 1997). In addition to affecting
blood vessel permeability, the tumor host environment also
influences MVD and vessel distribution. Human renal
carcinoma cells implanted into the kidney of nude mice
became highly vascularized, as revealed by immunohisto-
chemical staining for factor-VIII-related antigen, whereas
the s.c. growing tumors did not (Singh et al. 1994).
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Similarly, the vasculature of mouse B16.F10 melanoma
growing intracranially had a higher density, but a smaller
diameter, than the vasculature in s.c. growing tumors
(Kashiwagi et al. 2005).
Differential patterns of expression of angiogenic genes
accompany and are probably responsible for these host-
environment-induced differences in vascularization. Renal
cell carcinoma growth in the kidney resulted in a higher
Fig. 2 Efficacy of anti-angiogenic drugs is tumor-growth stage-
dependent. Rip-Tag2 mice develop pancreatic islet carcinomas in a
multistage process, which starts with the formation of hyperplastic
islets that, upon angiogenic switching, give rise to angiogenic islets.
Vessel sprouting facilitates the formation of solid tumors that progress
into large, intensely vascularized and invasive carcinomas. Four
different anti-angiogenic drugs were administered to mice at three
different stages of tumor progression. In the prevention trial, the
inhibitors were tested for their ability to block the onset of
angiogenesis. The intervention trial addressed whether the inhibitors
were able to slow down or stop tumor growth (n.d. not done). In the
regression trial, the drugs were tested for their ability to induce tumor
regression. Each of the treatment modalities exhibited a different
efficacy profile in the various stages. IT (initial tumor burden)
represents the size of the tumor at the beginning of the trials (10 weeks
for the intervention trial and 12 weeks for the prevention trial).
Adapted from Bergers et al. 1999, with permission from AAAS
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expression of fibroblast growth factor-2 (FGF-2) as
compared with subcutaneous growth of the same tumor
cells (Singh et al. 1994). Likewise, the decrease in
fenestration pattern and permeability in (glioblastoma)
tumors growing in the brain as compared with those
growing s.c. was accompanied by an elevated expression
of the receptors for VEGF, whereas expression of VEGF
itself did not differ per tumor location (Roberts et al. 1998).
Fig. 3 Tumor endothelial cell heterogeneity finds it origin at different
levels. Tumor endothelial heterogeneity occurs among different tumor
types or tumor cell subpopulations (a), among tumors grown in a
different host environment (b), in different stages of tumor progression
(c), and even within the same tumor vessel segment (d). a Tumor cells
are heterogeneous in their dependence on the vasculature. Isolation of
tumor cells based on their proximity to the blood vessels followed by
inoculation of these cells into mice results in tumors with different
growth characteristics. The tumors resulting from cells originally
localized proximal to the vasculature have a low growth rate, whereas
tumors originating from cells distal from the vessels grow more
aggressively, as they are less angiogenesis-dependent (Achilles et al.
2001; Yu et al. 2001). b The functionality of a gene and thus the
consequences of its dysfunctionality for vascular behavior depend on
the tumor host environment. Knock-out (ko) of hypoxia inducible
factor-1α (HIF) results in enhanced microvessel density (MVD) in
intracranially growing astrocytomas, but in decreased MVD when
tumors are growing in a subcutaneous microenvironment, as shown by
fluorescein-isothiocyanate-labeled tomato lectin perfusion (wt wild-
type). Reprinted from Blouw et al. (2003), with permission from
Elsevier. c As tumor growth progresses, the vasculature goes through
a repeated cycle of angiogenic stages, with concurrent changes in
vascular morphology throughout tumor progression. Immunohisto-
chemical staining for CD31 in B16.F10 melanoma growing subcuta-
neously in C57bl/6 mice. The tumors were harvested at ~25 mm3
(small volume), ~180 mm3 (intermediate), and ~520 mm3 (large).
Small tumors showed small vascular profiles, predominantly without a
lumen, whereas in intermediate and large tumors, vessels with
increasing lumen size existed next to small vessels that did not
contain a lumen. Large tumors exhibited strong zonal variations in
vascular diameter (unpublished; E. Langenkamp et al., manuscript in
preparation). d Intravascular heterogeneity for Tie2 expression exists
in human tumors; although some endothelial cells within one vessel
segment express Tie2, others do not (Fathers et al. 2005)
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Human ductal pancreatic adenocarcinoma grown in the
pancreas of nude mice exhibited enhanced expression of
VEGF with concomitant higher growth rate compared with
ectopic tumors in the abdominal wall (Tsuzuki et al. 2001),
and colon cancer xenografts grown in their orthotopic
location in the cecum wall produced higher levels of
interleukin (IL)-8, carcinoembryonic antigen, and multidrug
resistance protein-1 than their s.c. growing counterparts
(Kitadai et al. 1995).
In addition to influencing angiogenic gene expression, the
host microenvironment can also determine the functionality
of genes (Fig. 3b). SV40 T-transfected murine astrocytoma
cells grown either s.c. or in the brain of nude mice give
tumors with approximately similar vascular densities. How-
ever, upon knocking out the gene encoding hypoxia
inducible factor (HIF)-1α, the intracranially growing tumors
showed a 50% increase in vessel density, compared with the
wildtype tumor, accompanied by a 30% increased tumor cell
proliferation. In contrast, in the s.c. growing astrocytomas, a
50% reduction in vessel density and a 30% decrease in
tumor cell proliferation rate had been observed upon HIF-1α
knock-out (Blouw et al. 2003). Thus, the molecular and
cellular consequences of dysfunctional HIF-1α, and proba-
bly also of other proteins, are highly dependent on the
microenvironment. Together with the observation that the
vasculature in HIF-1α-deficient tumors growing in the brain
resembled those of the normal brain parenchyma, this lead to
the conclusion that HIF-1α-deficient astrocytomas were
impaired in their ability to induce angiogenesis. Instead,
they switched to the mode of co-opting pre-existing brain
vessels; this presented as an increased vessel density, as the
brain had a higher MVD than the tumor. In the avascular
subcutaneous space, this scenario of co-option was unfeasible.
The clinical relevance of host-environment-driven tumor
endothelial behavior was recently demonstrated by Morrissey
and colleagues (2007). They assessed patient biopsies from
prostate carcinoma metastasized to bone, liver, and lymph
node. The resulting tumors differed in MVD and expression
of angiogenic factors in a location-dependent manner. Bone
metastasis displayed the highest MVD, which correlated
with increased expression of factor XIII, plasminogen
activator inhibitor (PAI)-1, hepsin, and urokinase plasmin-
ogen activator (u-PA), but with decreased expression of the
pro-angiogenic growth factor Angiopoietin (Ang)-2, as
compared with liver and lymph node metastases. In
contrast, a study of vascularity in human primary invasive
mammary carcinomas and their respective metastases in
axillary lymph node failed to demonstrate a local tissue-
environment-induced difference in vascular density and
angiogenesis (Edel et al. 2000). Possibly, the number,
nature, and level of angiogenic genes active in a tumor
determines its capacity to overrule the host-environment-
driven control of tumor vascular behavior.
Spatiotemporal changes in angiogenic gene expression
during tumor outgrowth
As tumor growth progresses, the vasculature goes through a
repeated cycle of angiogenesis. Thus, the morphology of
the vasculature (Fig. 3c) and the accompanying angiogenic
make-up of the endothelium varies dynamically at any
given moment during tumor progression. Tumor growth-
stage-dependent heterogeneity in the expression of angio-
genesis-regulating molecules has been well documented.
For example, the distribution and the intensity of expres-
sion of VEGF, FGF-2, and IL-8 has been shown to differ in
small tumors versus large tumors. In orthotopic KM12SM
colon carcinoma, the zonal expression of these pro-
angiogenic molecules demonstrated intralesional variation
in which FGF-2 and IL-8 are predominantly expressed in
small tumors, and at the periphery of large tumors. At the
same time, VEGF was present in all zones, but with the
highest intensity in the center of large tumors (Kumar et al.
1998). In contrast, in a rat glioma model, VEGF was
expressed at equal levels in both small and large tumors at
2 weeks after tumor implantation into the brain, whereas
after 4 weeks, its expression was markedly induced at the
tumor rim (Holash et al. 1999). The importance of such
spatiotemporal variations in gene expression for tumor
vascular behavior has been nicely shown for VEGF. A high
dose of VEGF results in extensive remodeling of the
vasculature, leading to aberrant vessels with features of
destabilization and with pericytes loosely associated with
the endothelial cells (Pettersson et al. 2000; Ozawa et al.
2004). On the contrary, low levels of VEGF induce the
growth of vessels that are morphologically normal and
stable (Ozawa et al. 2004).
Zonal differences in transcriptional activity of the VE-
cadherin promotor has been documented in s.c. implanted
murine Lewis Lung carcinoma. VE-cadherin was absent in
a variety of vessels throughout the tumor, but intensely
expressed by the endothelium at the tumor periphery
(Prandini et al. 2005). A center-versus-periphery distribu-
tion of proteins has also been described in human tissues.
For example, clinical specimens of prostate carcinoma
metastases in liver and lymph node have been found to
display a heterogeneous distribution of fibulin-1; this ECM-
derived protein forms a component of the blood vessel wall
and was more intensely present at the periphery than in the
center of the secondary tumors (Morrissey et al. 2007).
In addition to intralesional heterogeneity, phenotypic
heterogeneity exists even between tumor endothelial cells
within one blood vessel segment (Fig. 3d). Fathers and
colleagues (2005) demonstrated by immunohistochemistry
that Tie2 expression in human colorectal carcinoma and
human melanoma grown s.c. in immune-compromised mice
was patchy, with Tie2-positive vessels existing next to
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Tie2-negative and Tie2-composite vessels. Examination of
clinical specimens of malignant melanoma and colorectal
carcinoma confirmed that Tie2-heterogeneity was common
in certain types of human cancers (Fathers et al. 2005).
These studies suggest that a widespread heterogeneity
occurs among tumor vascular profiles because of local
differences in growth factor production by tumor cells and/
or inflammatory infiltrates and stromal cells. As a conse-
quence, local differences exist in endothelial cell activation
status.
Molecular activation status of tumor endothelial cells
To date, scarce information is available concerning the
endothelial activation status in human and animal tumors.
Neither in-depth analyses of signal transduction activity
status nor detailed gene expression profiles in tumor
endothelial cells in varying conditions have been reported
as yet. This may be attributable to the limited availability
of antibodies specific for proteins in general and for
phospho-kinases for use in immunohistochemistry or
immunofluorescence applications, and of in situ hybrid-
ization protocols that can be widely applied for mRNA
localization studies. As tumor endothelial cells are
numerically under-represented in the tumor mass, whole
tumor RNA or protein isolates are not likely to reveal the
molecular signature of the endothelium. Many in vitro
studies make use of primary endothelial cells or
endothelial cell lines established from normal non-
diseased blood vessels. These endothelial cell cultures
do not represent the endothelial cells that are present in
the local tumor environment and influenced by often
unknown and rapidly changing concentrations of growth
factors, cytokines, and other angiogenic molecules.
Moreover, the biomechanics of blood flow and interac-
tions between blood-borne cells and endothelial cells are
not taken into account in cultures in vitro. Several studies
have reported the isolation of endothelial cells from
tumors by enzymatic digestion, followed by gradient
centrifugation or magnetic bead cell sorting and culture
(Bian et al. 2006; Miebach et al. 2006). These methods
influence endothelial cell behavior in various ways, thereby
inevitably inducing changes in kinome and transcriptome
status. Rapid changes in antigen expression upon culturing,
as evidenced by, for example, loss of vWF, VE-cadherin, and
CD31 (Miebach et al. 2006), demonstrate the high plasticity
of tumor endothelial cells similar to that of normal
endothelial cells, as described in the Introduction. Moreover,
information regarding their original location within the tumor
is lost, thereby possibly complicating the interpretation of the
experimental results even more.
Nevertheless, the isolation of tumor endothelial cells by
enzymatic digestion can provide a valuable source of
information regarding their transcriptome when immediate-
ly used for gene expression profiling. St. Croix and
colleagues (2000) have identified markers specifically
induced in endothelial cells from human colorectal carci-
noma through a comparison of gene expression profiles of
endothelial cells isolated from human colorectal carcinoma
and normal human colorectal tissue. Using the same
approach, the St. Croix group has recently identified genes
that are differentially expressed during pathological angio-
genesis in tumors grown in the liver in mice, on the one
hand, and during physiological angiogenesis in liver
regeneration, on the other hand (Seaman et al. 2007).
Application of laser microdissection enables the capture
of tumor endothelial cells from their (patho)physiological
environment, for subsequent in situ molecular profiling. By
combining immunohistochemistry-guided laser microdis-
section with microarray transcriptional profiling of ovarian
carcinoma vasculature, Buckanovich et al. have recently
revealed the overexpression of a set of genes in ovarian-
cancer-associated endothelium; these genes might be useful
as biomarkers for diagnosis and may shed light on the
molecular nature of angiogenic activation in this tumor
(Buckanovich et al. 2007). Reverse-phase protein micro-
array in combination with laser capture microscopy has
disclosed a reduction in phosphorylation of Akt in
metastatic breast cancer as a result of treatment with the
epidermal growth factor (EGF)-receptor inhibitor Erlotinib
(Wulfkuhle et al. 2008). If such a technique were to allow
the analysis of phosphorylated kinases from microdissected
tumor endothelium, a more detailed view of the activation
status of tumor endothelial cells and the heterogeneity
thereof in the various tumor segments would come within
reach.
Furthermore, by using in vivo or in vitro phage display,
alternatively combined with laser dissection microscopy
(Yao et al. 2005), differences in the composition and
properties of the vasculature of different pathological
lesions can be identified. Several studies have employed
this technique to identify peptide sequences that specifically
home to the vasculature of either pre-malignant hyper-
plasias or malignant solid tumors, but not to that of normal
tissue (Hoffman et al. 2003; Joyce et al. 2003; Yao et al.
2005). Although these studies have established that
different tumors express distinct repertoires of molecular
markers in their vasculature, detailed insight is lacking with
respect to the actual identity and meaning of such
differentially expressed markers.
Taken together, these studies suggest the existence of
extensive heterogeneity in the behavior of tumor endothelial
cells. Pharmacological intervention with anti-angiogenic
drugs targets the molecular control of microvascular behav-
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ior, either directly by interfering with tumor endothelial cell
signal transduction or indirectly by affecting angiogenic gene
expression by tumor and stromal cells. As the variation in
microvascular behavior is highly likely to find its basis in
tumor endothelial cell heterogeneity, this latter phenomenon
may be the underlying cause of the different responses to
pharmacological interference with hitherto unknown con-
sequences.
Efficacy of anti-angiogenic therapy
To date, anti-tumor therapies targeting the vasculature of
tumors have concentrated on two different strategies: either
they attack the endothelial cells in the tumor to disrupt the
vasculature and cause a rapid and selective shutdown of the
established tumor vascular network (the so-called vascular
disrupting agents or VDAs), or they aim to prevent the
processes that drive neovascularization (e.g., by using
angiogenesis inhibitors). VDAs cause acute occlusion of
existing tumor blood vessels, leading to rapid and massive
tumor cell necrosis, while they leave the blood flow in
normal tissues relatively intact. The largest group of VDAs
is the tubulin-binding combretastatins, several of which are
now being tested in clinical trials (Tozer et al. 2005). VDAs
will not be further addressed because of space limitations.
Most well-known examples of anti-vascular agents are
inhibitors of receptor tyrosine kinases (RTKs) and VEGF-
blocking antibodies. Their primary effect is the blockade of
new vessel formation, resulting in impaired tumor out-
growth. The exact biological consequence of treatment with
these inhibitors is unknown, but anti-angiogenic therapeutic
strategies have been documented to result in hypoxia
(Casanovas et al. 2005; Shaked et al. 2006), endothelial
cell apoptosis (Laird et al. 2002), and normalization of the
vasculature (Jain 2005). In rectal carcinoma patients, a
single infusion of the VEGF-specific antibody Bevacizu-
mab decreased tumor perfusion, vascular volume, MVD,
interstitial fluid pressure, and the number of viable
circulating endothelial progenitor cells (EPC) and increased
the fraction of tumor vessels covered by pericytes (Willett
et al. 2004). In a combination treatment regimen with
chemotherapy, this VEGF neutralizer prolonged the surviv-
al of patients with metastatic colorectal cancer (Hurwitz et
al. 2004). In 2007, ten new drugs with anti-angiogenic
activity have been approved by the FDA for the treatment
of cancer and age-related macular diseases, and at least 43
drugs were in clinical trials in the USA (Folkman 2007).
Nonetheless, anti-angiogenic drugs have not yet lived up
to their high expectations as a powerful new member of
anti-cancer drugs for use in daily clinical practice to control
tumor growth. While anti-VEGF-specific agents showed
promising anti-tumor results in preclinical studies, they did
not demonstrate an overall survival benefit when used as a
mono-therapy in phase III clinical trials (Jain et al. 2006;
Duda et al. 2007). Below, we will discuss why the limited
efficacy of anti-angiogenic therapies in the clinic may find
its origin in the under-appreciated heterogeneity of the
molecular activation status of endothelial cells in the tumor
vasculature.
Anti-angiogenic effects of anti-VEGF therapy
VEGF is considered one of the major regulators of
angiogenesis. Its potency and its consistent overexpression
in many tumor types together with the successful modula-
tion of tumor growth with anti-VEGFR2 antibodies and
small-molecular inhibitors of VEGFR2 in (pre)clinical
studies validate its usefulness as a therapeutic target for
anti-angiogenic therapy (Youssoufian et al. 2007). Activa-
tion of the VEGF-VEGF receptor signaling axis triggers
multiple signaling cascades that result in vascular perme-
ability, endothelial cell survival, proliferation, migration,
and differentiation, and mobilization of endothelial progen-
itor cells from the bone marrow (Hicklin and Ellis 2005).
Binding of VEGF to its receptors induces receptor
dimerization, resulting in the activation of its kinase activity
with consequent autophosphorylation. The phosphorylated
receptors recruit interacting proteins and induce the
activation of diverse signaling pathways. For example, the
phosphorylated tyrosine residue 1175 on VEGFR2 binds
phospholipase Cγ, which mediates activation of the
mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK)-1/2 cascade to induce pro-
liferation of endothelial cells. Moreover, the adaptor
molecule Shb binds to phosphorylated Tyr1175, thereby
activating phosphatidylinositol-3 kinase, which in turn
activates the serine/threonine kinase AKT/protein kinase B
pathway that mediates survival of the endothelial cells
(Olsson et al. 2006).
The effects of VEGF on the vasculature are tightly
regulated and vary depending on its microenvironmental
concentration, as discussed above. Low levels of VEGF
induce the growth of vessels that are morphologically
normal and stable; however, a high dose of VEGF
extensively remodels the vasculature, inducing enlargement
of the vessels and formation of bulbous vascular structures
resembling glomeruloid bodies (Ozawa et al. 2004). These
enlarged thin-walled pericyte-poor vessels (“mother” ves-
sels) are characterized by microvascular hyperpermeability,
edema, clotting of extravasated plasma fibrinogen, and
deposition of an extravascular fibrin gel matrix (Pettersson
et al. 2000). At high VEGF concentrations, mother vessels
evolve into distinct types of vessels, such as glomeruloid
microvascular proliferations, vascular malformations, but
also structurally normal capillaries (Dvorak 2007). The
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permeability properties of these vessels are different,
indicating that the response of vessels to VEGF can be
variable. Whereas mother vessels and glomeruloid-like
vessels become highly permeable in response to VEGF,
capillaries and vascular malformations do not (Nagy et al.
2006). Furthermore, VEGF affects vascular architecture, as
has been shown in gastric tumors in which the absence of
VEGF resulted in impaired vascular lumen formation
(Stoeltzing et al. 2004). In the quail chorioallantoic mem-
brane assay, vessel diameter increased maximally at high
VEGF doses, but MVD decreased (Parsons-Wingerter et al.
2006). In contrast, in human renal cell carcinoma, an
increased MVD was correlated with an increased expression
of VEGF and its receptors and of the VEGFR1-activating
factor placental growth factor, when compared with renal
cell carcinoma exhibiting a low MVD (Baldewijns et al.
2007). Thus, histological read-out of the effects of VEGF-
blocking therapy is complicated and may differ for a given
tumor type.
Treatment of HUVEC with the tyrosine kinase inhibitor
SU6668, which has affinity for both VEGFR2 and platelet-
derived growth factor receptor-β (PDGF-Rβ), resulted in
the inhibition of VEGF-induced proliferation. In vivo, this
compound significantly inhibited subcutaneous A431 epi-
thelial carcinoma growth in nude mice, by preventing
tumor expansion when administered at an early stage of
tumor growth, and by reducing tumor size when adminis-
tered to mice carrying late-stage carcinoma (Laird et al.
2000). Its effect on the tumor vasculature has been
established to be a reduction in tumor vessel density;
however, the underlying molecular events in the endothe-
lium have not been addressed. Furthermore, inhibition of
VEGFR2 with the tyrosine kinase inhibitor PTK787 in the
same tumor model caused a reduced occurrence of micro-
vessels in the interior of the tumors, whereas larger, more
mature vessels forming particularly at the tumor periphery
before initiation of the treatment remained unaffected
(Wood et al. 2000).
Molecular effects of anti-VEGF therapy on tumor
endothelial cells
Only a few studies have addressed the molecular events
induced in tumor endothelial cells upon pharmacological
treatment with angiogenesis inhibitors. In human colorectal
carcinoma liver metastases in nude mice, tumor vessels and
some tumor cells surrounding the vessels showed intense
staining for phosphorylated ERK and Akt. Upon treatment
of these mice with SU6668 or with the VEGFR2-specific
tyrosine kinase inhibitor SU5416, levels of phosphorylated
ERK and Akt in the tumor vasculature decreased (Solorzano
et al. 2001). Thus, treatment with these inhibitors resulted in
decreased signal transduction via at least Akt and ERK in
endothelial cells in vivo. Furthermore, Sasaki et al. (2007)
have demonstrated that in vitro treatment of murine mesen-
teric endothelial cells with the dual VEGFR2/EGF-R RTK
inhibitor AEE788 diminished ERK1/2 and Akt phosphoryla-
tion induced by TGF-α alone and by TGF-α combined with
VEGF. In vivo treatment of SW260CE2 orthotopic human
colon carcinomas with AEE788 alone or in combination with
conventional chemotherapy resulted in decreased phosphor-
ylation of the receptors for EGF and VEGF in endothelial
cells, with consequent reduction in the number and diameter
of blood vessels, increased apoptosis of endothelial and
tumor cells, and a decreased proliferation rate of the tumor
cells (Sasaki et al. 2007). In this tumor model, VEGFR2 and
EGF-R expression is restricted to the endothelial cells.
However, many other studies have reported the expression
of VEGFR2 and other RTK targets of anti-angiogenic drugs
by tumor cells in vivo (Cimpean et al. 2008; Xia et al. 2006;
Thaker et al. 2005; Kuwai et al. 2008). Therefore, the
localization of the molecular effects on the respective cell
types is critical for a proper understanding of the actual
mechanism of anti-angiogenic therapy in relation to thera-
peutic success or failure.
Tumor endothelial heterogeneity and efficacy
of anti-angiogenic drugs
Most pre-clinical successes with anti-angiogenic therapy
have been achieved when treatment is initiated at a very
early stage of tumor development, which is characterized
by synchronized blood vessel outgrowth. The studies by
Bergers et al. (1999, 2003) unambiguously showed that the
efficacy of angiogenesis inhibitors in the Rip-Tag2 model
of multistage pancreatic carcinoma is tumor-growth stage-
dependent (Fig. 2). This transgenic mouse model serves as
a prototype of spontaneously developing tumors in which
different (angiogenic) growth stages sequentially arise. At
3–4 weeks of age, hyperplastic islets begin to appear,
giving rise to angiogenic islets by switching on angiogen-
esis in the normally quiescent islet capillaries. This
transformation from normal to angiogenic islets is accom-
panied by an increase in vessel diameter that precedes
vessel sprouting and endothelial proliferation. Solid tumors
emerge at week 10 and progress into large, intensely
vascularized adenocarcinomas by week 13. These carcino-
mas display a higher vessel density and dramatic vessel
heterogeneity as revealed by hotspots of neovascularization
and irregular vessel diameters (Ryschich et al. 2002;
Bergers et al. 1999). The four angiogenesis inhibitors exert
different efficacies depending on the stage of carcinogen-
esis being targeted. The matrix metalloproteinase inhibitor
BB94, endostatin, and endostatin combined with angiosta-
tin perform best in inhibiting both early and mid-stage
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disease, i.e., in preventing angiogenic switching in dysplas-
tic lesions or blocking expansive tumor growth. In contrast,
the inhibitor of endothelial cell proliferation TNP470
reduces the mass of bulky end-stage tumors but is
ineffective in preventing angiogenic switching in the early
stage of tumor growth. Of note, the SV40 transgene is not
synchronically activated in all pancreatic β-cells, resulting
in a temporal spectrum of developing neoplastic foci. This
spatiotemporal heterogeneity of tumor development within
the pancreas is of considerable value for assaying pharma-
cological interventions at different developmental stages of
tumor growth, as it reflects the biological diversity of
cancer development in humans.
The tumor growth-stage-specific efficacy of the drugs
suggests that qualitative differences exist in the angiogenic
vasculature at the different tumor growth stages. The
contribution of the various kinases, molecular targets of
anti-angiogenic drugs, to tumor growth may be different at
the different stages of tumor vascular development. Hence,
the fraction of the tumor vasculature that is affected by a
specific drug given at one specific moment may vary for
the different growth stages. Several studies have indicated
that, for an efficient anti-tumor effect, at least ~90% of the
tumor vasculature needs to be attacked. Targeting of a blood-
coagulation-inducing coaguligand to the tumor vasculature
could only induce long-term tumor regression upon affecting
the complete tumor vascular network. Incomplete thrombosis
of the tumor vasculature attributable to the absence of
detectable levels of target epitope on the neovasculature
permitted the local survival of tumor cells and the regrowth
of the tumors (Huang et al. 1997). Moreover, for anti-
angiogenic agents, a partial attack of the vasculature has
been shown to be devoid of strong anti-tumor activity. A
Tie2-antagonizing antibody effectively reduced MVD and
tumor growth in a WM115 melanoma, a tumor of which
95% of the vasculature is positive for Tie2. In contrast, in the
HCT116 colon carcinoma, of which only 70% of the vessels
expressed Tie2, Tie2 inhibition had no effect (Fathers et al.
2005). A metronomic dosing schedule of anti-angiogenic
drugs in which the drugs are administered at low(er) doses
for a prolonged period of time (Kerbel and Kamen 2004)
may provide a means of keeping the neovasculature under
continuous pharmacological pressure to circumvent incom-
plete exposure.
The question arises as to whether the anti-tumor effects
and also the development of resistance to treatment are
predominantly attributable to an effect on the tumor
endothelium, or whether the surrounding tumor cells are
also involved. Evidence is emerging that VEGF may have
an additional role in tumor growth through the stimulation
of VEGF receptors on tumor cells (Hicklin and Ellis 2005;
Thaker et al. 2005). Hence, VEGFR2 expression on tumor
cells may contribute to the anti-tumor effects of VEGFR2-
targeted anti-angiogenic drugs. Nevertheless, several
other studies have established the efficient tumor-growth-
inhibitory effect of anti-angiogenic therapy solely mediated
through the targeting of epitopes selectively present on the
tumor vasculature (Fathers et al. 2005; Sasaki et al. 2007).
Redundancy in angiogenic factors
and neovascularization types provides routes
for resistance
Although increasing evidence demonstrates the occurrence
of genetic alterations such as chromosomal translocations
and aneuploidy in tumor-associated endothelial cells
(Streubel et al. 2004; Hida et al. 2004, 2008), these cells
are still considered to be more genetically stable than tumor
cells, as they are not oncogenically transformed. Therefore,
anti-angiogenic therapy in theory can circumvent the
problem of therapy-induced resistance. Indeed, the natural
inhibitor of angiogenesis, endostatin, demonstrated anti-
tumor activity and a lack of resistance upon repeated
treatment after re-growth in three different mouse xenograft
tumor models. After several treatment cycles, no tumors
recurred upon discontinuation of therapy, indicating that
resistance to endostatin has not developed in these tumors
(Boehm et al. 1997). Unfortunately, emerging preclinical
and clinical data show that resistance to anti-angiogenic
therapy is a fact that we have to face. The presence of an
array of different angiogenic molecules provides the tumor
with a variety of redundancy pathways. When VEGF is
inhibited, FGF-2 and other pro-angiogenic factors may be
present to take over the control of neovascularization. For
instance, 10 days of treatment with a VEGFR2-function-
blocking antibody initially resulted in a significant impair-
ment of tumor formation in the Rip-Tag2 model. This was
associated with a marked decrease in vessel density,
vascular dilation, and permeability. After a treatment period
of 4 weeks, this phase of stable disease was followed by
regrowth of the tumors, which was supported by a second
wave of angiogenesis. This second wave was controlled by
FGF and possibly also by other pro-angiogenic factors such
as the Ephrins and angiopoietins, as suggested by their
upregulation in both tumor and endothelial cells upon
VEGFR2 blocking treatment (Casanovas et al. 2005). In
concordance with this, FGF-2 and PDGF-BB have recently
been described as having an important synergistic role in
tumor neovascularization and metastasis, without any
involvement of VEGF (Nissen et al. 2007).
The capacity of tumors to employ other mechanisms
than VEGF- or FGF-driven sprouting angiogenesis to
acquire a blood supply, such as intussusceptive angiogen-
esis, recruitment of endothelial progenitor cells, vessel co-
option, or vasculogenic mimicry, provides even more
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possibilities for evading anti-angiogenic therapy. Under the
influence of the VEGFR2 inhibitor ZD6474, tumor angio-
genesis in the brain was blocked with a concomitant
decrease in vessel density, but tumor growth was not
inhibited. Instead, tumor progression sustained via co-
option of pre-existing vessels (Leenders et al. 2004).
Interestingly, VEGFR2 was also present on the tumor cells
(personal communication, Dr. W.P.J. Leenders), which may
imply that the ZD6474-induced switch to vessel co-option
partially involved a tumor-cell-mediated effect. Further-
more, cessation of treatment with the VEGFR2-inhibiting
compounds AG-013736 and AG-028262 resulted in rapid
regrowth of the vasculature in the Rip-Tag2 model of
spontaneous pancreatic carcinoma and in s.c. implanted
Lewis lung carcinoma. Both agents caused a 50%-60% loss
of the tumor vasculature, as demonstrated by immunoflu-
orescent detection of CD31, but empty sleeves of basement
membrane were left behind. These sleeves and accompa-
nying pericytes functioned as a scaffold for quick tumor
vessel regrowth after treatment was stopped (Mancuso et al.
2006). In addition, recruitment of EPCs circulating in
the blood may contribute to vessel formation under the pres-
sure of anti-vascular therapy. Treatment of Lewis lung
carcinoma- and human melanoma-bearing mice with the
vascular disrupting agent Oxi-4503, a second generation
derivative of combretastatin, induced the mobilization of
EPCs to become incorporated into the vasculature (Shaked
et al. 2006).
Efficacy of combination therapy to inhibit tumor
angiogenesis
The redundancy in strategies acquired by the tumor to
establish a vasculature suggests that anti-tumor therapy
might benefit from a combination approach. Indeed, several
studies have shown an enhanced anti-tumor effect when
combining two vascular targeting agents. The VEGFR2
blocking agent SU5416 efficiently blocked the angiogenic
switch in premalignant lesions in the Rip-Tag2 model but
was incapable of inducing tumor regression in middle- or
end-stage disease. On the contrary, SU6668, which has a
high PDGF-Rβ inhibitory effect in addition to VEGFR2
blockade, has proved more effective in inhibiting end-stage
tumor growth. Combining these two agents, and thereby
targeting angiogenic switching of the tumor endothelium
and PDGF-Rβ activity on pericytes, was highly efficacious
against all stages of pancreatic islet carcinogenesis (Bergers
et al. 2003). Inhibition of either VEGFR1 or VEGFR2
signaling in murine B16 melanoma alone had no significant
effect on subcutaneous tumor growth and metastasis
formation, whereas blocking both receptors successfully
inhibited solid tumor progression and formation of lung
metastasis (Gille et al. 2007). Similarly, the anti-tumor
efficacy of Oxi-4503 increased when combined with an
anti-angiogenic agent (Shaked et al. 2006), and combining
anti-VEGFR2 therapy with an MMP inhibitor caused more
extensive vascular regression in Rip-Tag2 tumor growth
(Mancuso et al. 2006). Combination of anti-angiogenic
therapy with conventional chemotherapy and radiotherapy
can also give rise to synergistic tumor growth inhibition;
these combinations have been and are still being investi-
gated both in preclinical and clinical studies (Kerbel and
Kamen 2004) but will not be addressed further as this
subject is beyond the scope of this review.
In summary, although monotherapy aimed at blocking
angiogenesis-associated tumor endothelial signal transduc-
tion can exert powerful effects in preclinical tumor models,
resistance to therapy due to endothelial heterogeneity and/
or by switching to a different angiogenic mode is a realistic
threat. Combination therapies blocking multiple molecular
pathways in tumor endothelial cells, tumor cells, and
stromal cells concomitantly are hence warranted. For
success, the dosing of the right drug(s) at the right time
needs to be carefully considered and may be guided in the
near future by phospho-kinase screening prior to treatment.
Concluding remarks
Microvascular endothelial cells and tumor endothelial cells
display remarkable heterogeneity in their cellular and
molecular characteristics, which are spatiotemporally con-
trolled by their (patho)physiological microenvironment. In
vitro studies have provided an enormous wealth of
information regarding the way that endothelial cells
respond to stimuli of various sorts, and in rather a short
time, a significant number of drugs affecting pro-angiogenic
signal transduction in cancer have reached the stage of
clinical testing. The lack of comprehensive knowledge of
the factual molecular status of tumor endothelial cells in
their complex in vivo environment, which is dynamically
changing under the influence of a plethora of ill-defined
processes, now poses an important challenge for the
biomedical field. Not only technological advances in
analyzing the complex kinome, transcriptome, and epige-
netics of tumor endothelial cells and the local molecular
effects of anti-angiogenic drugs on these cells are essential
prerequisites for progress (G. Molema, M. Mrug, E.
Verpoorte, K. Schutze, R. Bischoff, H. Struijker-Boudier,
manuscript in preparation), but also the identification of
proper biomarkers and new methods for molecular imaging
of anti-angiogenic effects on tumor vasculature will be
instrumental for future developments (Iagaru et al. 2007).
A number of other issues could not be addressed here
because of space constraints but should not go unnoticed as
they may have importance for future research. They include
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the widespread use of xenografted human tumors in
immune-compromised animals and of rapidly growing
mouse tumors implanted in avascular pockets. Extrapola-
tion of data from these models to the clinical situation is
difficult, if not impossible. More and more animal tumor
models based on orthotopic “spontaneous” tumor out-
growth are becoming available to the research community,
and these may overcome part of the extrapolation problems
encountered with the artificial models. Furthermore, the
majority of studies on the molecular behavior of tumor
endothelial cells and anti-angiogenic drug effects have been
performed in young mice that are otherwise perfectly
healthy. Recently, Klement and colleagues (2007) have
demonstrated that vascular aging and atherosclerosis are
accompanied by retarded tumor outgrowth and concurrent
diminished MVD, microvascular proliferation index, and
TEM1 and VEGFR2 expression, whereas acute tumor
hypoxia increases. Moreover, treatment with cyclophospha-
mide in a metronomic dosing schedule previously shown to
exert anti-angiogenic effects is less effective in old
atherosclerotic mice (Klement et al. 2007). Similarly, high
glucose levels associated with aging but also with diabetes
type-2 associated with a Western-style diet have been
shown to impair some essential signaling pathways and
general EPC functions (Chen et al. 2007). This may have
repercussions for the day-to-day repair of small microvas-
cular damage by progenitors and for EPC-related repair of
larger cardiovascular insults and cellular processes in tumor
angiogenesis.
The remarkable progress made in unraveling the molec-
ular control of vascular development and tumor angiogenesis
has paved the way into the next era. By expanding our
knowledge regarding the way that microvascular endothelial
cells molecularly control their function in the different
organs, we may become able to fine-tune culture conditions
to maintain their behavior ex vivo. This might create new
opportunities for integrating the correct endothelial cells
with the appropriate function in engineered tissue constructs
and for creating valuable in vitro screening systems for use
in, for example, drug development. For tumor angiogenesis,
the newly aquired knowledge should definitely assist in the
design of rational drug treatment schedules that will become
an integral part of daily clinical practice.
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